Aim 1: Characterize factors that modify the effect of APOE 4 on cognitive decline and AD biomarkers.
Aim 2: Support local research in ADRD.
Aim 1: Support ALZ-NET research data collection for patients being clinically treated with Lecanemab and other anti-amyloid antibodies in the real world, with a focus on early detection of ARIA.
Aim 2: Leadership role in roll-out of digital cognitive assessment in the Keck Healthcare system.
Aim 1: Integrate multi-disciplinary team in ADRC clinical core and Neurology Memory Disorders Clinic.
Aim 2: Collaborate with Family Medicine in provision of neurological expertise to CMS GUIDE program.
Aim 2: Support inclusive research, through GeneScreen, with a focus on outreach to underserved groups in Los Angeles County, including those seen in the Department of Health Services. Share data with national networks such as ALZ-NET. Organize numerous educational events.
Aim 3: Participate in national database initiatives (NACC, SCAN, ADNI, NCRAD, NIAGADS, CLARiTI).
Aim 1: Characterize factors that modify the effect of APOE 4 on cognitive decline and on AD ATN(vi) biomarkers, with an emphasis on vascular, metabolic, and ethnic influences, in concert with the new Center for Personalized Brain Health (CPBH).